Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Ionis Pharmaceuticals Inc | IONS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
42.45 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 34.32 - 54.4446 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 42.45 | USD |
Ionis Pharmaceuticals (IONS) Options Flow Summary
Ionis Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.19B | 145.75M | - | 787.65M | -366.29M | -2.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ionis Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IONS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 41.00 | 42.72 | 40.385 | 41.30 | 780,919 | 1.45 | 3.54% |
1 Month | 44.95 | 44.95 | 40.385 | 42.35 | 942,644 | -2.50 | -5.56% |
3 Months | 51.71 | 51.98 | 40.385 | 44.50 | 1,085,326 | -9.26 | -17.91% |
6 Months | 45.85 | 54.4446 | 40.385 | 47.37 | 1,116,301 | -3.40 | -7.42% |
1 Year | 35.76 | 54.4446 | 34.32 | 44.38 | 1,128,720 | 6.69 | 18.71% |
3 Years | 43.14 | 54.4446 | 25.04 | 39.61 | 1,116,369 | -0.69 | -1.60% |
5 Years | 73.80 | 75.14 | 25.04 | 46.21 | 1,083,589 | -31.35 | -42.48% |
Ionis Pharmaceuticals Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). |